Collaborators
Prof Mario Pirisi, Università del Piemonte Orientale "A. Avogadro", 2008
Guest Lectures
Treatment Landscape of hepatocellular carcinoma, Roche ACT academy, Faculty, Dublin (Ireland), 2019
Cancer Immunotherapy in Early or Intermediate HCC, ESMO Asia (Faculty), Singapore, 2019
ILCA Meeting General Sessio II: Clinical TrialsChair, ILCA Annual Meeting 2019, Chicago (USA), 2019
Systemic therapy and new sequences in HCC, What’s next in advanced HCC (Faculty), LondonIndustry Sponsored Event, 2019
Keynote Lecture: Targeting immune regulation within tumours, Imperial College LondonShort Course on Immunology (Faculty), Hammersmith Hospital, 2018
Delivering Precision Oncology in Intermediate-stage hepatocellular cancer, EASL International Liver Meeting Faculty Early Morning Workshop, Amsterdam (NL), 2017
Liver Cancer: Pathogenesis, Screening and Treatment, European HIV Hepatitis Co-infection Meeting Conference (EHHC), British HIV Association, 2015
Personalised cancer care: where were we, where are we, where are we going?, Western Norway Health Care Trust, Helse Vest, Faculty, Stavanger (Norway), 2015
Hepatitis, HIV and malignancy, International Workshop on Co-infection HIV and Hepatitis, London, 2015
Systemic inflammation as a prognostic domain in liver cancer, International Conference: Hepatocellular carcinoma from biology to surgery, IRCCS S. De Bellis, Castellana Grotte, Bari (Italy), 2015
Hepatocellular carcinoma and novel molecular targets: a new hope for the future?, Università degli Studi del Piemonte Orientale "A. Avogadro", Novara (Italy), 2011
Introduction to Drug Discovery, University of Oxford - Doctoral Training Centre, Oxford (UK), 2011
Research Student Supervision
Abdulrahman,A, Circulating free DNA in the diagnosis and molecular phenotyping of hepatocellular carcinoma
Black,J, PRRT in Metastatic Parangagliomas
Brown,M, The role of Axl in acquired sorafenib resistance in hepatocellular carcinoma
Choo,Y, Treatment-stage migration in the use of sorafenib for hepatocellular carcinoma
Cortellini,A, Family history of malignancy as a putative predictive factor of response to cancer immunotherapy
D’Alessio,A, Neoadjuvant immunotherapy of HCC
Dettorre,G, The systemic inflammatory response in patients with COVID-19 and Cancer
Dettorre,G, The acute phase response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection
Enica,A, Circulating free DNA as a biomarker of benefit to immunotherapy in HCC
Fessas,P, Intra-tumoral heterogeneity influences the tumour microenvironment in primary and secondary HCC.
Gramenitskaya,D, The gut microbiome as a source of predictive biomarkers of response to immunotherapy in HCC.
Hashimoto,T, The natural history of HIV-associated hepatocellular carcinoma
Kalofonou,F, Immunotherapy outcomes in elderly patients undergoing checkpoint inhibitor therapy for cancer.
Kaneko,T, Phenotypic characterisation of HIV-associated hepatocellular carcinoma
Kythreotou,A, The relationship between the sytemic inflammatory response and PD ligands regulation in NSCLC
Mi,E, The inflammatory response in NSCLC patients undergoing immunotherapy
Muhammed,A, The systemic inflammatory response as a predictive marker in HCC patients treated with immunotherapy
Naeem,M, Antibiotic therapy as a prognostic marker in HCC patients treated with immunotherapy
Patel,M, OnCovid: natural history and outcomes of cancer patients during the COVID19 epidemic
Shiraz,J, Systemic Inflammation in the prognosis of HIV-associated hepatocellular carcinoma
Siddique,A, Regulation of Immune-tolerogenic pathways in hepatocellular carcinoma
Su,Y, Regulation of PD ligands in acquired sorafenib resistance in hepatocellular carcinoma
Tsoti,S, The role of Axl in the pathophysiology of neuroendocrine tumours
Victor,S, The relationship between PD ligands expression and activation of the innate immunity in hepatocellular carcinoma
White,S, Identification and clinical significance of PD-L1 positive circulating tumor cells in neuroendocrine tumors
Wong,CN, Tumour mutational burden (TMB) as a stratifying biomarker in HCC.
Yen,C, Treatment-stage migration in the use of sorafenib for hepatocellular carcinoma